"Targeted Therapy in ovarian cancer: novel agents and predictive biomarkers" by Li Bei
  
 
 
Artigo de revisão bibliográfica 
Mestrado Integrado em Medicina 
 
 
 
 
Targeted therapy in ovarian cancer: novel agents and predictive 
biomarkers 
 
 
 ´
 
 
 
 
Autor: Li Bei 
 
Orientador: Prof. Doutor Rui Henrique 
 
Co-Orientador: Dra. Deolinda Pereira 
 
 
 
Porto, Junho de 2011 
 
2 
 
Abstract 
Ovarian cancer is the second most common gynecological malignancy and the leading 
cause of death from gynecological cancer. Most women present with advanced stage 
disease, having a poor prognosis even with adequate treatment. Cure is unlikely for 
advanced disease. Despite the high rate of initial response to chemotherapy, the majority 
of women will develop recurrent disease, and, thus, new therapeutic options are required. 
Molecularly directed therapy has been developing rapidly for ovarian cancer, either as 
single therapy or in association with chemotherapy. Bevacizumab, an anti-VEGF 
antibody, is among the most promising agents as in phase III clinical trials it appeared to 
improve survival. PARP inhibitors may also have an important role for patients with 
BRCA1/BRCA2 mutations. This article will review the various targeted approaches under 
investigation in ovarian cancer, its current developments, clinical benefits, safety and 
also searching for predictive biomarkers of response to treatment. 
 
Introduction 
Ovarian cancer is the second most common gynecological malignancy and is 
by far the most lethal gynecological cancer. For the year 2010, it is estimated 
that 21,880 new cases will be diagnosed and that 13,850 patients will die from 
ovarian cancer [1]. The overall prognosis of this malignancy is poor, with a five-
year overall survival of 45% for all stages [1]. 
Most ovarian cancers are of epithelial origin and its staging is performed 
according to the FIGO staging system, which differentiates early stage tumors 
(stage I-II) from advanced disease (III-IV). The later corresponds to 75% of 
patients and carries a poor prognosis. Most women present with advanced 
disease due to the unspecificity of symptoms and the often asymptomatic 
course in the early stages of this malignancy. The current therapeutic approach 
consists on the combination of maximal cytoreductive surgery followed by first-
line chemotherapy based on platinum compounds (carboplatin or cisplatin) plus 
paclitaxel. Intraperitoneal drug administration and neoadjuvant chemotherapy 
are clinically acceptable variations of treatment regimens as they may benefit 
some patients, but it should be selected on an individualized basis. 
 
Managing recurrent ovarian cancer 
There are different criteria for defining relapse in ovarian cancer. These include  
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continuous rise in CA-125 level, CA-125>100 U/ml, and /or radiographic 
(usually CT) or symptomatic evidence of recurrence.  
Response rate is expected in over 70% of women who receive standard 
platinum and paclitaxel as first-line treatment [2]. However, the majority of 
patients treated for advanced disease will relapse, requiring a second and, 
possibly, more treatments [3, 4]. The most beneficial sequence of treatments 
has not been established. Recurrent patients can respond to platinum re-
treatment and the response rate is directly related to the length of time elapsed 
since the last course of platinum chemotherapy to the documented recurrence 
disease [5]. The second-line treatment has been studied on the basis of 
improved progression-free survival (PFS) or overall survival (OS). Given that 
recurrent disease is currently incurable, palliation of symptoms and extending 
survival with minimum drug toxicity are the goals of management. For platinum-
sensitive disease (relapse more than six months after completing first-line 
chemotherapy), a platinum based therapy continues to be the main regimen, 
often in combination with a drug like paclitaxel [6], gemcitabine [7] or pegylated 
liposomal doxorubicin (PLD) [8]. More recently, PLD in association with 
trabectedin has been approved for platinum-sensitive cases [9]. Expected 
response rates vary from 30% to 40% or even higher, especially for those with a 
treatment free interval larger than 24 months [10, 11]. On the opposite, 
platinum-resistant disease (remission-free period less than six months) is 
typically treated with a single non–platinum agent, such as PLD, gemcitabine, 
paclitaxel, or topotecan and the reported response rate for each of these drugs 
is in the 10-20% range [12]. Thus, the current scenery of the treatment of 
ovarian epithelial cancer (EOC) demands new approaches which might 
contribute to improve patients‘ survival. Targeted therapies appear to be 
promising and several clinical trials are ongoing or have been published over 
the last few years. Among these, compounds targeting tumor-related 
angiogenesis have provided the more promising results and as such they 
constitute the main focus of this review. 
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Angiogenesis as therapeutic target 
The growth of malignant tumors and metastatic capacity are both highly 
dependent upon angiogenesis. Any increase in tumor burden must be 
accompanied by an increase in vessel formation to adequately supply the tumor 
mass. In addition, these new vessels are leaky because of the fragmented 
basement membranes, creating an easy access into circulation and, thus, 
facilitating metastization. Interestingly, studies evaluating the vessel count in 
EOC concluded that the degree of neovascularization is of prognostic 
significance in both early-stage and advanced disease [13, 14].   
Ovarian tumors, like many other malignancies, overexpresses proangiogenic 
factors, including vascular endothelial growth factors (VEGFs), fibroblast growth 
factors (FGFs), angiopoietin, platelet-derived growth factors (PDGFs), and pro-
angiogenic cytokines such as tumor necrosis factor alpha and interleukins 6 and 
8 [15]. Among the markers of increased angiogenesis, VEGF is the most 
investigated in ovarian cancer. VEGFs constitute a family of growth factors that 
includes VEGF-A, -B, -C, -D and placental growth factor (PGF). VEGF-A is 
generally referred to as VEGF. VEGFs bind to a family of receptors (VEGFR-1, 
-2 and -3) with intrinsic tyrosine kinase activity. VEGFR-2 is believed to be the 
major mediator of the proangiogenic effects of VEGF-A [16]. VEGF activation 
promotes endothelial cell proliferation and migration for the formation of new 
blood vessels and increases permeability of existing blood vessels to allow for 
the leakage of multiple plasma proteins, including those playing a role in 
angiogenesis [17]. There is evidence that VEGF can recruit bone-marrow 
derived endothelial progenitor cell into sites of neovascularization [18]. 
Evidence based on measurement of serum VEGF levels suggests that VEGF 
may be a useful serological biomarker for clinical diagnosis, prognosis, follow-
up of tumor metastasis and monitoring the efficacy of therapy [19, 20]. There is 
still some controversy about the concept of VEGF as an independent prognostic 
factor for EOC. Whereas some agree with this statement [21, 22], others 
believe that VEGF prognostic significance is related to its correlation with FIGO 
stage [23]. 
Based on VEGF pathway inhibition, it is possible do adopt different blocking 
strategies: inhibition of the VEGF ligand itself (e.g., Bevacizumab), inhibition of 
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the VEGF receptor (e.g., Tyrosine Kinase Inhibitors - TKIs) or neutralizing 
VEGF by administrating soluble receptors (e.g., VEGF Trap). 
In fact, angiogenic stimulation is not limited to VEGF. Endothelial cells express 
PDGF receptor (PDGFR) which is activated by its ligand – PDGF - for 
recruitment of pericytes and maturation of the microvasculature. PDGF 
secretion by tumor cells may also recruit stromal cells that further support 
angiogenesis through the release of VEGF [18]. FGF produced by tumor cells 
also promotes angiogenesis via endothelial cell proliferation, migration and 
differentiation [24]. PDGF and FGF are implicated in resistance to 
VEGF/VEGFR agents, explained by the fact that while an anti-VEGF agent is 
active, other proangiogenic factors that are overexpressed may restore 
angiogenesis [25]. Therefore, using a multi-target antiangiogenic strategy is a 
desirable option to counteract this resistance. 
 
Targeting VEGF ligand – Bevacizumab 
Bevacizumab (Avastin®) is an intravenously administrated humanized 
monoclonal IgG antibody directed against human VEGF-A, and this drug acts 
by binding to VEGF-A isoforms preventing them to activate its receptors. It is 
currently approved for treating various advanced solid tumors: colorectal, breast, 
renal cell carcinoma, non-squamous non-small cell lung cancers, and 
glioblastoma. 
Phase II and III clinical trials results suggest that bevacizumab is a promising 
strategy in recurrent or persistent ovarian cancer, either as single agent or in 
combination with chemotherapy, as detailed below. 
 
Phase II clinical trials 
Two important studies, involving patients with relapsed ovarian cancer treated 
with bevacizumab as single agent (15 mg/kg every 21 days) were the first to 
demonstrate evidence of activity for a targeted agent in ovarian cancer. The 
Gynecology Oncology Group (GOG) 170 D study reported by Burger and 
colleagues [26] enrolled 62 patients with either platinum-sensitive or platinum-
resistant disease with no more than 2 prior chemotherapy regimens. Cannistra 
et al [27] recruited 44 patients only platinum-resistant who failed the topotecan 
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or liposomal doxorubicin therapy and could have received up to three prior 
chemotherapy regimens. Burger et al. [26] documented an objective response 
rate of 21% and 52% stable disease. At 6 months, 40% of patients were 
progression-free, median PFS was 4.7 months and OS 16.9 months. Cannistra 
et al. [27] demonstrated a response rate of 16% and 61.4% with stable disease 
as their best response. The median PFS was 4.4 months and the median OS 
10.7 months. These results were encouraging since they were achieved by 
bevacizumab alone, contrasting with the lack of effectiveness in breast, colon or 
lung cancer. 
Regarding adverse events, Burger et al. reported two cases of deep vein 
thrombosis (3.2%), one case of grade 4 proteinuria (1.6%) and six cases of 
grade 3 hypertension (9.7%) [26]. The toxicity profile was different in 
Cannistra‘s study. They had five patients (11.4%) with gastrointestinal (GI) 
perforation, one of which was fatal, and other three patients developed arterial 
thromboembolic disease [27]. Three deaths (myocardial infarction, GI 
perforation and hypertensive encephalopathy) were suspected to be related 
with bevacizumab. Those who experienced GI perforation had receive three 
prior chemotherapy regimens compared with the rest of the group who had 
receive two prior chemotherapy regimens and none experienced perforation. 
Thus, higher GI perforation incidence in this study might be related with the fact 
that its population had more advanced disease [27]. 
Other trials suggested that bevacizumab in combination with chemotherapy 
(carboplatin, paclitaxel, cyclophosphamide or topotecan) is effective in 
advanced ovarian cancer. Two studies with chemotherapy-naïve patients with 
advanced ovarian carcinoma, concluded that carboplatin plus paclitaxel and 
bevacizumab (PCB) as first line therapy is safe and effective, with similar results 
[28, 29]. Micha et al. submitted 20 patients to six cycles of PCB and found 80% 
response rate; 23.3% and 25% of cycles were associated with grade 3 and 4 
neutropenia, respectively. Two additional patients developed deep vein 
thrombosis that required hospitalization, although neither case appeared to be 
related to bevacizumab. No GI perforation, severe thrombocytopenia or anemia 
were reported [28]. Penson et al. recruited 62 patients. The study differs from 
the previous because patients maintained bevacizumab for a year after six to 
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eight cycles of PCB. Their results were the following: 76% of best overall 
response, median PFS duration of 29.8 months and 58% of patients were free 
from progression at 36 months. Treatment was associated with some important 
toxicities: two cases of pulmonary embolism, two GI perforation (grade 1 and 4), 
four cases of neuropathy and 14 patients developed neutropenia, all occurring 
during the chemotherapy phase of treatment. No grade 4 toxicities were seen 
during maintenance therapy with bevacizumab [29]. 
Metronomic chemotherapy (MC), which is intended to prevent tumor 
angiogenesis, is based on more frequent and low-dose drug administrations 
compared with conventional chemotherapy. This model of treatment 
suppresses tumor growth in experimental models [30, 31] and was encouraged 
by studies in metastatic breast cancer where MC was associated with clinical 
improvement and drop in VEGF levels with minimal toxicity [32]. To assess the 
efficacy of MC in ovarian cancer, two phase II trial were developed. 
Combination of bevacizumab and metronomic chemotherapy with 
cyclophosphamide was applied by Chura et al. [33], which conducted a trial of 
15 heavily pre-treated patients with bevacizumab in a lower dose than the 
previous trials (10 mg/kg) plus cyclophosphamide. A response rate of 53.3% 
and a median duration of progression free survival of 3.9 months were found. 
Despite being heavily pre-treated and having confirmed intra-abdominal cancer, 
no GI perforations were reported. In another study, Garcia et al. [34] enrolled 70 
patients with platinum-sensitive and platinum-resistant disease and 
administered the same treatment regimen. They reported a 24% response rate, 
63% stable disease and 56% of patients were free from disease at 6 months. 
The median time to progression and median survival time were 7.2 months and 
16.9 months, respectively. However, GI perforation and thromboembolism 
occurred (4% of cases each), along with three treatment-related deaths. The 
levels of angiogenesis markers (VEGF, E-selectin, and thrombospondin-1) of 
less than half of participants were measured and were not associated with 
clinical outcome. Table 1 summarizes all phase II trials mentioned above.  
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Phase III clinical trials 
The first two phase III studies designed to study addition of bevacizumab to 
standard chemotherapy (carboplatin/paclitaxel) in front-line treatment, GOG-218 
and ICON-7, have already reported their preliminary results. Both have PFS as 
the primary endpoint. GOG-218 [35] is a three-arm, placebo-controlled, 
randomized trial involving 1,873 stage III or IV patients. The 3 treatment arms 
are: placebo plus chemotherapy followed by placebo maintenance (Arm 1), 
bevacizumab plus chemotherapy followed by placebo maintenance (Arm 2), 
and bevacizumab plus chemotherapy followed by bevacizumab maintenance 
(Arm 3). Dosage of bevacizumab used was 15 mg/kg. PFS was defined 
according to either Response Evaluation Criteria in Solid Tumors (RECIST), or 
CA-125 levels defining progressive disease according to Gynecologic Cancer 
Intergroup (GCIG) criteria. Using both criteria simultaneously, a significant 
improvement in PFS for maintenance bevacizumab group compared with 
control group was detected (PFS 14.1 months vs. 10.3 months for Arm III vs. 
Arm I, p<0.0001), but no significant benefit of bevacizumab plus chemotherapy 
without maintenance (p=0.08). The PFS difference censoring CA-125 was 18 vs. 
12 months for Arm III vs. Arm I (p<0.0001), allowing for the same conclusion 
about the benefit of bevacizumab maintenance. The toxicity profile was 
favorable, with 23% of grade 2 or greater hypertension. Across the 3 arms, GI 
perforation/fistula events were observed in less than 3% of patients. The low 
rate of GI perforation may be explained by the fact that patients with a history of 
small bowel obstruction were excluded. On the other hand, the ICON-7 [36] 
study is an open-label randomized trial which recruited 1,528 patients with high-
risk stage I-II or stage IIb to IV disease. It allocated patients into two different 
arms: standard carboplatin/paclitaxel (Arm 1) and carboplatin/paclitaxel plus low 
dose bevacizumab (7.5 mg/kg) followed by bevacizumab (Arm 2). Their PFS 
was measured according to RECIST criteria and the results differed significantly 
(18.3 months vs. 16 months for Arm 2 vs. Arm 1, p=0.001). The toxicity profile 
was similar to that of GOG-218 with 1.3% GI perforation (compared with 0.4% 
in the control arm) and 18.3% grade 3 or greater hypertension. Table 2 
compares the results of GOG-218 and ICON-7. 
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When comparing patients‘ profiles, several characteristics distinguish these two 
phase III trials (see figure 1). GOG-218 enrolled poorer-prognosis patients (only 
advanced disease was accepted) and only 34% had optimal debulking stage III 
disease (compared with 73% in ICON7). The dosage of bevacizumab in ICON-7 
was half of that of GOG-218 and the duration of exposure was shorter. Both 
trials suggest an advantage of bevacizumab maintenance in ovarian cancer, but 
the absolute benefit in terms of PFS is modest, and neither trial showed an 
overall survival benefit. Thus, more phase III trials using bevacizumab are 
required and those that are ongoing are depicted in Tables 3 and 4, concerning 
first-line or relapsed ovarian cancer treatment, respectively. 
 
Toxicity 
The adverse events associated with bevacizumab in ovarian cancer trials are 
similar to those described in other solid tumors, mainly comprising hypertension, 
proteinuria, thrombosis and GI perforation [37]. Gastrointestinal perforation is a 
potentially life-threatening complication of major concern. It is estimated to 
occur in up to 2.4% of patients treated with bevacizumab in colorectal cancer 
[38]. Cannistra‘s study was stopped prematurely due to the higher than 
expected incidence of GI perforation [27]. The recent GOG-218 and ICON-7 
trials provided relevant information in this regard because the rate of potentially 
fatal GI perforation was lower than suggested by earlier phase II trials. The 
confirmation of safety of bevacizumab is obviously critical for any further 
investigation on this drug.  Retrospective reviews of small studies prior to GOG-
218 and ICON-7 trials results indicated that incidence of GI perforation may be 
slightly higher in pretreated patients and when a history of bowel obstruction 
exists [39, 40]. 
 
VEGF Trap 
VEGF trap (Aflibercept) is a fusion protein containing the VEGF binding 
domains of both VEGFR-1 and 2 linked through the Fc region of a human IgG1. 
Aflibercept binds VEGF-A and neutralizes all VEGF-A isoforms plus PGF. The 
clinical applicability of this drug in age-related macular degeneration is already 
in phase III trials. Experiments in ovarian models suggested that VEGF Trap 
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may reduce malignant ascites and tumor burden [41, 42]. In Tew et al. study 
[43], 162 platinum-resistant patients who failed the subsequent topotecan or 
liposomal doxorubicin therapy were treated at dosage levels of 2 mg/kg or 4 
mg/kg every 2 weeks. Five partial responses in a sample size of 45 patients 
(11%) were obtained. Grade 3–4 adverse events included: hypertension (9%), 
proteinuria (4%), encephalopathy (2%) and renal failure (2%). Two cases of GI 
perforation and one of pulmonary embolism were considered drug-related. In 
another study, Columbo et al. [44] reported the results of VEGF Trap in patients 
with advanced ovarian cancer and symptomatic ascites requiring frequent 
paracentesis. Aflibercept 4mg/kg was administered every 2 weeks. Primary 
endpoint was repeat paracentesis response rate (RPRR), defined as at least a 
doubling of time to the first paracentesis compared to a baseline average. Eight 
out of ten evaluable patients achieved a RPRR response as per protocol. Grade 
3-4 adverse events included bowel obstruction (40%) nausea, vomiting (30%), 
anorexia, edema, general health deterioration (20%) and 1 case of bowel 
perforation. Thus, further data on survival rates is needed to back up VEGF 
Trap use. Finally, a phase I/II trial assessing the efficacy of VEGF Trap 
associated with docetaxel in recurrent ovarian cancer, as well as other phase 
II/III trials investigating VEGF Trap for recurrent malignant ascites are ongoing.  
 
VEGFR TKIs 
In contrast to bevacizumab anti-VEGF action, small molecule TKIs bind to the 
intracellular component of VEGFRs and therefore block downstream signal 
transduction pathways activated by VEGFs and other ligands of the VEGF 
family. These small molecule inhibitors are also active against other tyrosine 
kinases, thus playing a multi-target role that may contribute to its antitumor 
effects. 
Several VEGFR TKIs are under investigation in patients with recurrent ovarian 
cancer, either as monotherapy or in combination therapy. Given the 
convenience of oral administration, it is likely that these drugs will have an 
important role as maintenance therapy in advanced ovarian cancer. 
Cediranib (AZD2171) is a highly potent inhibitor of VEGFR1, VEGFR2, 
VEGFR3, PDGFR and c-KIT. Hirte and co-workers [45] recruited 60 patients 
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with recurrent disease who had received no more than one prior chemotherapy 
regimen. Evaluation of platinum-sensitive and resistant patients was done 
separately. The median time to progression (TTP) and median survival time for 
all patients were 4.1 months and 11.9 months, respectively. Matulonis et al. [46] 
used Cediranib in the same context for 46 patients but up to two prior 
chemotherapy regimens were permitted. Partial responses were observed in 
17% of patients, and 13% exhibited stable disease. PFS was 5.2 months. Both 
trials had to reduce the initial 45 mg daily dose to 30 mg, due to toxicity. ICON 6, 
a double blind placebo controlled phase III trial in recurrent platinum-sensitive 
patients, is currently testing this agent in association with standard initial 
chemotherapy. Patients are randomized to one of three groups: 
carboplatin/paclitaxel, carboplatin/paclitaxel/cediranib or carboplatin/paclitaxel/ 
cediranib, with cediranib maintenance. 
Sorafenib is a tyrosine kinase inhibitor targeting BRAF and other receptor 
kinases (VEGFR, PDGFR, FLT3, c-KIT), approved for the treatment of 
advanced inoperable hepatocellular carcinoma and advanced renal cell cancer. 
Either acting as single agent or associated with gemcitabine, available data 
demonstrated significant disease stabilization, but at a cost of increased tocixity, 
including grade 3 and 4 hand-foot syndrome [47, 48]. The combination therapy 
tested in a phase II trial with two anti-VEGF agents, sorafenib and bevacizumab, 
was not well tolerated requiring dose reductions in the majority of patients with 
advanced solid tumors. Despite the toxicity, partial responses were seen in six 
(43%) of 13 patients with ovarian cancer [49]. Biomarker analyses in Matei‘s 
trial included measurement of extracellular signal-regulated kinase (ERK) and 
BRAF expression in tumors and phosphorylation of ERK (pERK) in peripheral-
blood lymphocytes (PBLs) before and after 1 month of treatment. ERK and 
BRAF were expressed in all tumors and exploratory analyses indicated that 
pERK in post-treatment PBL specimens was associated with PFS [48]. Front-
line treatment with sorafenib in association with carboplatin/paclitaxel in 
advanced ovarian cancer is being tested in a phase II study.  
Single-agent use of sunitinib demonstrated modest activity in recurrent 
platinum-sensitive ovarian cancer, but only at the 50 mg intermittent dose 
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schedule, suggesting that dose and schedule may be vital considerations in 
further evaluation of this agent [50]. 
Pazopanib inhibits VEGFR, PDGFR, and c-KIT. As single therapy in recurrent 
ovarian cancer, with CA-125 decrease as parameter of response, it showed a 
biochemical response in eleven of 36 patients (31%) and 18% of overall 
response in patients with measurable disease [51]. 
BIBF-1120 is a triple angiokinase inhibitor, targeting VEGFR, PDGFR and 
FGFR tyrosine kinases. A sustained inhibition characterizes this novel agent 
[52]. Results from a randomized, placebo-controlled study using maintenance 
therapy with BIBF 1120 following chemotherapy in relapsed ovarian cancer, 
reported a 9 month PFS rate of 15.6% for BIBF 1120 and 2.9% for placebo. 
This suggests that maintenance therapy with BIBF 1120 could delay disease 
progression in patients who previously responded to chemotherapy [53]. 
Clinical trials with imatinib, a PDGFR and c-KIT inhibitor had disappointing 
results, with almost negligible activity as a single agent [54, 55]. 
 
Polyadenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors  
The defects in DNA repair pathway in a specific group of ovarian cancer 
patients (those with BRCA1 or BRCA2 mutations), underlie the successful 
results obtained in the clinical trials involving PARP Inhibitors. Mutations in 
either of those genes confer a lifetime risk of breast cancer between 60 and 
85%, and a lifetime risk for ovarian cancer between 15 and 40% [56]. BRCA1 
and BRCA 2 proteins are critical for genome integrity maintenance since they 
participate in DNA double-strand break (DSBs) repair via homologous 
recombination (HR), an error free pathway. Poly (ADP-ribose) polymerase 
(PARP) is a key nuclear enzyme involved in the repair of DNA single-strand 
breaks (SSBs) using the base excision repair pathway. PARP inhibitors 
generate DNA SSBs, which may lead to DSBs [57-59]. Non-cancerous cells 
from patients inheriting BRCA 1/ 2 mutations retain a single wild-type copy of 
the BRCA 1/2 gene, allowing for sufficient HR mediated DNA repair to take 
place in the presence of PARP inhibition. In contrast, the BRCA1/2-mutated 
cancer cells, with both alleles inactivated, have to repair DSBs by preferential 
use of an error-prone mechanism, leading to excessive accumulation of DNA 
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damage. This difference between tumor and normal cells explains why PARP 
inhibitors can be lethal for tumor cells while normal cells are spared [59-61]. The 
concept of synthetic lethality is applied here. It is defined as the situation where 
two defective pathways acting individually have no effect, but in combination 
lead to cell death [61]. Preliminary observations from two phase II trials of 
Olaparib (AZD2281), aimed at advanced hereditary ovarian cancer, are 
encouraging.  Audeh et al. [62] studied a group of chemo-refractory ovarian 
cancer patients and reported an objective response rate and clinical benefit rate 
(objective response rate and/or confirmed >50% decline in CA125) of 33% and 
57%, respectively, at 400 mg twice daily dose. Lower activity was observed with 
100 mg twice daily. Toxicities were generally mild. Grade 3 toxicity occurred 
infrequently, and comprised primarily nausea (7%) and leukopenia (5%). Fong 
et al. [63] reported 40% response rate (complete or partial responses and/or 
CA125 responses). There was a significant association between the clinical 
benefit rate and platinum-sensitivity.  
PARP inhibitors were initially thought to benefit only the small group of women 
carrying germline mutations of BRCA1 or BRCA2. However some tumors 
display the so called ―BRCAness‖, characterized by a phenotypic similarity of 
sporadic cancers with those carrying BRCA mutations, in the absence of 
germline mutation [64]. This phenomenon may occur due to aberrant promoter 
methylation [65]. Baldwin et al. analyzed a group of sporadic ovarian cancers 
and found BRCA1 promoter methylation in 15% of cases [66]. ―BRCAness‖ may 
thus allow for the use of PARP Inhibitors in some sporadic ovarian cancer, 
increasing the number of women diagnosed with ovarian cancer which might 
benefit from this drug. 
 
HER Inhibitors 
The human epidermal growth factor receptor (HER, EGFR or ErbB) family 
consists of four members of tyrosine kinase receptors: HER-1 (commonly 
termed EGFR), HER-2/Neu, HER-3, and HER-4. A number of ligands, the EGF-
related peptide growth factors, bind specifically to the extracellular domain of 
HER leading to dimerization of the receptor with any of the four members of the 
HER family molecules, forming homo- and heterodimers. Subsequently, 
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intracellular proteins involved in signaling pathways are activated, resulting in 
modulation of gene transcription. HER-2 and HER-3 are functionally incomplete 
receptors - HER-2 lacks ligand-binding activity whereas HER-3 has a defective 
kinase activity - but they are able to form heterodimeric complexes with other 
HER receptors generating potent cellular signals. Abnormal activation of the 
HER pathway is responsible for malignant transformation and tumor growth 
through the inhibition of apoptosis, cellular proliferation, promotion of 
angiogenesis, and metastasis. This abnormal activation may be initiated by one 
or several mechanisms, including increased production of growth factors, 
overexpression of receptors in cells, as well as mutation of genes encoding for 
these receptors or certain downstream enzymes [67-69]. There are two main 
strategies for targeting the HER family: monoclonal antibodies (e.g., 
trastuzumab, cetuximab) or tyrosine kinase inhibitors–TKIs (e.g., gefitinib, 
erlotinib). 
Data concerning EGFR and HER-2 overexpression and their association with 
prognosis in ovarian cancer is controversial. EGFR overexpression rate varies 
from 9–62% [70], depending on the antibody, the assay and the cutoff standard. 
Expression of HER-2 has traditionally been evaluated by immunohistochemistry 
with inconsistent prognostic results for EOC [71-73]. Owing to these disparate 
results, fluorescence in situ hybridization (FISH) analysis of HER-2 amplification 
has been applied to a series of EOCs in an attempt to lessen the difficulty in 
quantifying immunohistochemical staining. Recently, GOG analyzed primary 
tumors from 133 women with suboptimally-resected and advanced stage EOC 
using FISH, and concluded that HER-2 amplification is rare and has no 
predictive or prognostic value [74]. 
Thus, it not surprising that already concluded phase II trials evaluating anti-HER 
therapies have provided disappointing results. Reports on cetuximab (Erbitux®) 
in unselected HER status ovarian cancer, acting as singe-agent or in 
combination with carboplatin, with or without paclitaxel, did not meet satisfactory 
outcomes [75-77]. We know already from the colorectal cancer that KRAS 
mutations may predict unresponsiveness to cetuximab. Hence, it would be 
interesting in future studies to search for those mutation and compare the 
response to cetuximab in groups of tumors with wild-type or mutant KRAS. 
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Schielder et al. analyzed 12 different serum markers before and during 
cetuximab monotherapy and found no correlation between PFS and marker 
changes, but high levels of baseline markers were associated with earlier 
disease progression [75]. Unsatisfactory results were also seen with 
pertuzumab as single agent in heavily pretreated patients [78]. Other study in 
which pertuzumab was administrated with gemcitabine in a placebo controlled 
randomized phase II study. The objective response rate was 13.8% in 
gemcitabine + pertuzumab regimen, compared to 4.6% in patients receiving 
gemcitabine + placebo. Moreover, low HER-3 mRNA expression may predict 
pertuzumab clinical benefit [79]. Trastuzumab (Herceptin®), an anti-HER-2 
antibody widely used in breast cancer, was tested as a single agent in GOG 
160 phase II study, obtaining an overall response rate of 7.3% in the 41 eligible 
patients with HER-2 overexpression (1 CR and 2 PR). Furthermore, there was 
no relationship between the serum level of the extracellular domain of HER2 
and patient‘s outcome. This study showed a relatively low frequency of HER-2 
amplification in unselected ovarian cancers (11,4%), assessed by 
immunohistochemistry [80]. 
Because TKIs have the convenience of oral administration, Gefitinib (ZD1839, 
Iressa) was given in monotherapy to unscreened patients but none reached 
complete response and only 37% had stable disease. A decrease in both EGFR 
and p-EGFR was observed following gefitinib therapy in >50% of patients, 
providing a proof of effective targeting in a clinical setting, despite the lack of 
clinical benefit [81]. The GOG 170C phase II trial also tested gefitinib alone and 
reported that one of 27 (4%) patients had partial response and four of 27 (15%) 
patients were free from progression at 6 months. Because mutations in the 
tyrosine kinase domain region of EGFR have been associated with sensitivity to 
gefitinib in non-small cell lung cancer (NSCLC), exons 18 to 21 of EGRF were 
sequenced. Interestingly, the only tumor harboring a mutation in catalytic 
domain corresponded to the patient which experienced an objective response 
[82]. The combination of gefitinib with tamoxifen was found to be ineffective in 
advanced ovarian cancer since there were no tumor responses [83]. Another 
small molecule inhibitor, erlotinib (Tarceva®) demonstrated limited activity for 
recurrent ovarian cancer, with 6% partial response and 44% stable disease [84]. 
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Erlotinib has also been tested in combination with bevacizumab. The objective 
response rates were 15% (2/13 patients) and 54% (7/13 patients) had stable 
disease. Due to lack of improvement over bevacizumab therapy alone and two 
incidents of fatal gastric perforation, the erlotinib plus bevacizumab study was 
stopped [85]. 
 
Estrogen Receptor 
Since ovarian cancers commonly express estrogen receptors (ER), trials have 
been carried out to whether they might constitute therapeutic targets. The 
hormonal agent tamoxifen is routinely used to treat breast cancer in women 
whose tumors express ER. The recent Cochrane review of tamoxifen in ovarian 
cancer was unable to provide evidence-based recommendations as 
comparative studies assessing the effectiveness of tamoxifen are not available. 
The small phase II trials that were reported thus far showed an overall objective 
response rate of 9.6% (range: 0-52%), whereas 31.9% (range: 0-83%) of 
patients achieved disease stabilization [86]. Thus, questions such tamoxifen 
improving survival and symptom control or whether hormone receptor status is 
useful in selecting patients for tamoxifen treatment remain unanswered. 
Concerning the aromatase inhibitor letrozole (Femara®), phase II trials results 
indicated disease stabilization rather than improvement [87-90]. In a study 
comprising 42 patients with ER+ relapsed ovarian cancer, Smyth et al. reported 
9% partial remission and 42% stable disease, according to radiological 
response criteria. Using CA-125 levels as a response marker, they observed 
17% of responders (decrease > 50%) and 26% of patients had stable disease 
(no doubling of CA-125) at 6 months. In addition, the CA-125 response was 
more likely in cancers with the highest level of ER expression [87]. 
 
Other potencial targets 
Oregovomab, a monoclonal antibody against CA-125, was tested in a phase III 
trial. This monoimmunotherapy after front-line therapy did not demonstrate 
clinical benefit compared to the placebo group [91]. The folate receptor α-FR is 
overexpressed in 90% of ovarian cancers [92]. Farletuzumab (MORAb-003) is 
in a phase III trial comparing the efficacy and safety of intravenous carboplatin 
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and taxanes with and without farletuzumab in individuals with first platinum-
sensitive relapse. Angiopoietin is involved in an angiogenic pathway parallel to 
VEGF pathway. AMG 386 is a peptide-Fc fusion protein that inhibits 
angiogenesis by neutralizing the interaction between the Tie2 receptor and 
angiopoietin 1 and 2. A recent phase II showed increased PFS with the AMG 
386 and paclitaxel association compared to paclitaxel alone [93]. 
 
Conclusions 
Contrarily to other common malignancies (e.g., breast, colon, and lung cancers), 
targeted therapy in epithelial ovarian cancer is still at its inception. Most phase II 
trials testing bevacizumab indicated that VEGF targeting might be an efficient 
strategy for ovarian cancer treatment. The results from the latest phase III trials 
GOG-218 and ICON-7, however, showed only a modest benefit in progression-
free survival. Importantly, the potentially fatal GI perforation events observed in 
previous studies were lower in phase III trials (<3%), although we should be 
aware that the eventual risk factor for perforation (bowel obstruction) was an 
exclusion criteria in GOG-218 trial. This study revealed that treatment of ovarian 
cancer with carboplatin, paclitaxel and bevacizumab followed by bevacizumab 
maintenance may be an effective first-line treatment option. However, the 
optimal dosage of bevacizumab and its duration is still unclear. More consistent 
judgments about bevacizumab use can be made when OS results are matured 
and other phase III trials report their preliminary results. Moreover, the RECIST 
criteria traditionally used to evaluate objective response rate might not be the 
best for assessing antiangiogenic agents, as these agents appear to slow tumor 
growth and do not cause tumor shrinkage. The search for adequate response 
biomarkers is also a critical issue as current studies only rely on the unspecific 
CA-125 measurement. Notwithstanding, even before assessing therapeutic 
response, physicians need biomarkers that will identify which patients will or will 
not benefit from the addition of the novel agent. This requires a better 
understanding of ovarian cancer tumorigenesis and a broad search for key 
genetic and epigenetic alterations. In this regard, BRCA1/BRCA2 mutations or 
the ―BRCAness‖ status might constitute an example of this effort if further 
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studies are able to prove the efficacy of PARP inhibitors in defined subgroups of 
patients. 
Given the multiplicity and redundancy of aberrant pathways involved in ovarian 
cancer, it is unlikely that inhibition of a single cascade will be highly effective, 
thus contributing to resistance to VEGF-targeted therapy. Combining multiple 
antiangiogenic agents may be, then, a solution. An additional question needs to 
be answered, i.e., whether it is most effective to inhibit different signaling 
pathways (horizontal blockade) or different molecules within the same pathway 
(vertical blockade). 
Finally, the cost-effectiveness of adding targeted therapy to ovarian cancer 
treatment has to be thoroughly analyzed but only when a significant impact on 
survival has been proven and when more definite answers to the questions 
raised above are provided by additional research in this field. 
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Study Patients characteristics Intervention Results Common grade ≥ 3 
adverse effects 
Burger et al. 
(2007) [26] 
62 patients with persistent 
or recurrent of EOC or PPC  
1-2 CT regimens 
42% were platinum 
resistent 
Single agent 
bevacizumab      
(15 mg/kg q21) 
CR: 3% 
PR: 18% 
SD: 52% 
PFS: 4.7 mos 
6mPFS: 40% 
OS: 16.9 mos 
Hypertension: 9.7% 
GI events: 6.5% 
TED: 3.2% 
Proteinuria: 1.6% 
 
Cannistra et al. 
(2007) [27]
a
 
44 patients with recurrent 
platinum-resistant EOC or 
PPC after discontinuing 
topotecan or liposomal 
doxorubicin. 
2-3 CT regimens 
Single agent 
bevacizumab 
(15 mg/kg q21) 
CR: 0% 
PR: 16% 
SD: 61.4% 
PFS: 4.4 mos 
6mPFS: 27.8% 
OS: 10.7 mos 
GIP: 11.4% 
Small intestinal 
obstruction: 9.1% 
Hypertension: 9.1% 
TED: 6.8% 
 
Micha et al. 
(2007) [28] 
20 patients with Stage III or 
IV EOC, PPC and FTC 
85% optimally cytoreducted 
First line  
carboplatin + 
paclitaxel + 
bevacizumab 
(15 mg/kg q21) 
CR: 30% 
PR: 50% 
SD: 5% 
 
Neutropenia:18 pts 
TED: 2 pts
b 
Hypertension: 2 pts 
Neuropathy: 1pt 
Penson et al.  
(2010) [29] 
62 patients with advanced 
EOC, PPC, FTC and UC 
82% optimally cytoreducted 
First line 
carboplatin + 
paclitaxel + 
bevacizumab 
(15 mg/kg q21) 
with maintenance 
of bevacizumab for 
a year 
CR:21% 
PR:55% 
SD:21% 
PFS: 29.8 mos 
36mPFS: 58% 
OS: NR 
 
CT phase 
Neutropenia: 14 pts 
Metabolic: 8 pts 
Hypertension: 6 pts 
Thrombocytopenia: 
4pts 
Neuropathy: 4pts  
TED: 2 pts 
GIP: 2 pts (grade 1,4)  
Maintenace phase 
Hypertension: 5 pts 
Chura et al.  
(2007) [33] 
15 patients with recurrent 
ovarian cancer 
Median number of previous 
chemotherapy regimens = 
8 
Bevacizumab  
(10 mg/kg q14) + 
cyclophosphamide 
CR: 13.3% 
PR: 40% 
SD: 20% 
PFS: 3.9 
Pancreatitis: 1 pt 
Diarrhea: 1 pt 
Garcia et al.  
(2008) [34]  
70 patients with recurrent 
EOC  and PPC 
1-3 prior CT regimens 
40% were platinum-
resistant 
Bevacizumab  
(10 mg/kg q14) + 
cyclophosphamide 
CR: 0% 
PR: 24% 
SD: 63% 
OS: 16.9 mos 
TTP: 7.2 mos 
6mPFS: 56% 
Lymphopenia: 14 pts 
 Hypertension:11 pts 
GI obstruction: 6 pts 
Proteinuria: 3 pts 
GIP: 3 pts (grade 2,4,5) 
TED: 3 pts 
Table 1. Reported phase II trials of bevacizumab in ovarian cancer 
a
 Study stopped prematurely due to high rate of GIP 
b
TED cases were not directly attributed to bevacizumab  
Abbreviations: CR, complete response; CT, chemotherapy; EOC, epithelial ovarian cancer; FTC, fallopian tube 
cancer; GIP, gastrointestinal perforation; mos, months; NR, not reported; PFS, progression-free survival (6m, 6 
months; 36m, 36 months); PPC, primary peritoneal cancer; PR, partial response; pt(s), patient(s); q14, every 14 
days; q21, every 21 days; SD, stable disease; TED, thromboembolic disease (either arterial or venous); TTP, time 
to progression; UC, uterine carcinoma. 
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 GOG 218 ICON-7 
Characteristics 
 
Arm 1 
CP 
Arm 2 
CP+Bev 
Arm 3 
CP+Bev 
→Bev 
maintenance 
Arm 1 
CP 
maintenance 
Arm 2 
CP+Bev 
→Bev 
maintenance 
 
Median PFS 
    RECIST or CA-125 
    RECIST only 
 
10.3 mos 
12.0 mos 
 
11.2 mos 
NR 
 
14.1 mos 
18.0 mos 
 
NA 
16 mos 
 
NA 
18.3 mos 
Select adverse events 
Hypertension 
GIP/fistula 
Venous thromboembolism 
Arterial thromboembolism 
Proteinuria 
 
7.2%
a
 
1.2% 
5.8% 
0.8% 
0.7% 
 
16.5%
a
 
2.8% 
5.3% 
0.7% 
0.7% 
 
22.9%
a
 
2.6% 
6.7% 
0.7% 
1.6% 
 
2.1%
b
 
1.3% 
1.7% 
1.3% 
0.1% 
 
18.3%
b
 
2.1% 
4.3% 
2.7% 
0.5% 
Figure 1. Differences between two phase III trials of first line treatment with chemotherapy alone or in 
combination with bevacizumab: GOG 128 and ICON – 7 (see table 2 for results). 
Abbreviations: EOC, epithelial ovarian cancer; FTC, fallopian tube cancer; PPC, primary peritoneal cancer; 
q21, every 21 days; RECIST, Response Evaluation Criteria in Solid Tumors. 
 
 
Table 2. Results of two phase III trials of first line treatment with chemotherapy alone or in combination with      
bevacizumab: GOG 218 and ICON-7 
 
a 
grade ≥ 2 
b 
grade ≥ 3 
Abbreviations: Bev, Bevacizumab; CP, carboplatin plus paclitaxel; GIP, gastrointestinal perforation; NA, not 
applicable; NR, not reported; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid 
Tumors. 
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Trial Type No. 
patients 
Patients 
characteristics 
Design End 
point 
GOG-262 Open label, 
randomized 
625 Stage III or IV, 
suboptimal debulking 
Carboplatin + paclitaxel q21 ± 
(optional) Bev→Bev maintenance 
vs carboplatin q21 + paclitaxel q7 ± 
(optional) Bev→Bev maintenance 
PFS 
GOG-252 Open label, 
randomized 
1500 Stage II-IV, optimal or 
suboptimal debulking 
Paclitaxel IV + carboplatin IV + 
Bev→Bev maintenance  vs 
paclitaxel IV + carboplatin IP + 
Bev→Bev maintenance vs 
paclitaxel IV and IP + cisplatin IP + 
Bev→Bev maintenance  
PFS 
Trial Type No. 
patients 
Patients characteristics Design End 
point 
GOG 213 Open label, 
randomized 
660 CR to first-line platinum-
taxane therapy and DFI≥ 
6 months; previous Bev 
allowed 
Carboplatin + paclitaxel ±  
Bev→Bev maintenance in 
surgical and non-surgical 
candidates 
OS 
OCEANS Placebo-
controlled, 
double-blind 
randomized 
487 Platinum-sensitive Carboplatin + gemcitabine ± 
Bev→Bev maintenance 
PFS 
AURELIA Open label, 
randomized 
300 Platinum-resistant Liposomal doxorubicin or 
paclitaxel or Topotecan ± 
Bev→Bev maintenance 
PFS 
Abbreviations: Bev, bevacizumab; IP, intraperitoneal; IV, intravenous; PFS, progression-free survival; q7, every 
week; q21, every 21 days; vs, versus. 
Table 4. Ongoing phase III trials with bevacizumab in relapsed ovarian cancer 
Table 3. Ongoing first-line phase III trials with bevacizumab in ovarian cancer 
 
Abbreviations: Bev, bevacizumab; CR, complete response; DFI, disease-free interval; OS, overall survival; 
PFS, progression-free survival; vs, versus. 
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Study No. 
Patients 
Target Treatment Response 
Rate (RECIST) 
SD Outcomes 
(months) 
OS 
(months) 
Tew et al. 
(2007) [43] 
162 VEGF-Trap Aflibercept 11% NR NR NR 
Hirte et al.  
(2008) [45] 
60 VEGFR1,-2,-3,  
PDGFR 
Cediranib Pl-s: 2 pts confir. 
Pl-r: 1pt unconfir. 
NR TTP: 4.1 11.9 
Matulonis et 
al. (2009) [46] 
46 VEGFR1,-2,-3,  
PDGFR 
Cediranib Pl-s: 2 pts 
Pl-r: 6 pts 
6 pts PFS 5.2 Not 
reached 
Matei et al. 
(2010) [48] 
71 VEGFR,PDGFR, 
FLT3, c-KIT, Raf 
Sorafenib 3.4% 34% 6mPFS: 24% NR 
Welch et al. 
(2010] [47] 
43 VEGFR,PDGFR, 
FLT3, c-KIT 
Sorafenib + 
gemcitabine 
4.7%  
27.9% (CA-125) 
23.3 TTP: 5.4 13.3 
Biagi et al. 
(2011) [50] 
30 VEGFR, PDGFR, 
c-KIT 
Sunitinib 3.3%  
10% (CA-125) 
53% PFS: 4.1 NR 
 
Friedlander et 
al. (2010) [51] 
36 VEGFR, PDGFR, 
c-KIT 
Pazopanib  31% (CA-125) NR MDR: 113 
days 
NR 
Ledermann et 
al. (2009) [53] 
84 VEGFR, PDGFR, 
FGFR 
BIBF-1120 NR NR 9mPFS: 15.6 
vs 2.9* 
NR 
*placebo 
Abbreviations: conf., confirmed; unconf, unconfirmed; FGFR,  fibroblast growth factor receptor; MDR, median duration of 
response; NR, not reported; MDR, median duration of response;  OS, overall survival; PDGFR, platelet-derived growth factor 
receptors; PFS, progression-free survival (6m, 6 months; 9m, 9 months); Pl-r, platinum resistant; Pl-s, platinum-sensitive; 
pt(s), patient(s); pt(s), patient(s); RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; TTP, time to 
progression; VEGF, vascular endothelial growth factor ; VEGFR, vascular endothelial growth factor receptor; vs, versus.  
 
Table 5. Published phase II trials of non-bevacizumab VEGF pathway inhbitors 
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Trial No. 
patients 
Target Treatment Response SD PFS 
Schielder et al. 
(2009) [75] 
25 EGFR Cetuximab 1 pt 9 pts 2.1 mos 
Gordon et al. 
(2006) [78] 
61 HER-2 
dimerization 
Pertuzumab 4.3% 6.8% 6.6 wks 
Makhija  et al. 
(2010) [79] 
130 HER-2 
dimerization 
Pertuzumab+
gemcitabine 
13.8% vs 
4.6%* 
NR NR 
Bookman et al. 
(2003) – GOG 
160 [80] 
41 HER-2 Trastuzumab 7.3% NR NR 
Posadas et al. 
(2007) [81] 
24 EGFR Gefitinib 0% 37% NR 
Schielder et al. 
(2005) – GOG 
170 C [82] 
27 EGFR Gefitinib 1 pt NR 6mPFS: 
15% 
Wagner et al. 
(2007) [83] 
56 EGFR, ER Gefitinib +  
tamoxifeno 
0% 29% NR 
Gordon et al. 
(2005) [84] 
34 EGFR Erlotinib 6% 4% NR 
Nimeri et al.  
(2008) [85] 
13 EGFR, VEGF Erlotinib +  
bevacizumab 
2 pt 7 pts NR 
Table 6. Published phase II trials of human epidermal growth factor receptor (HER) inhibitors  
 
*gemcitabine and placebo 
Abbreviations: HER, human epidermal growth factor receptor, EGFR, epidermal growth factor receptor; 
ER, estrogen receptor; NR, non reported; PFS, progression-free survival (6m, 6 months); pt(s), 
patient(s); SD, stable disease; vs, versus. 
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